SHH and skin basal cell carcinoma: In our quest to identify more efficacious mechanism-driven targeted therapy for the multiple BCCs that occur in patients with NBCCS, we have found that pharmacologic inhibition of Shh and inflammatory signaling pathways using combined administration of inhibitors of these signaling pathways leads to almost complete abrogation of BCC growth.